# Therabron Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therabron-therapeutics

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.therabron.com
- Total disclosed funding: $6.8M
- Latest round: Series B (Nov 9, 2015)
- Investors on record: 1

## About

Therabron Therapeutics focuses on developing innovative therapeutics for patients with severe respiratory diseases, leveraging advanced biopharmaceutical technologies to enhance treatment outcomes.Therabron Therapeutics, founded in 2007 and headquartered in Rockville, US, develops therapeutics for respiratory diseases. The company received a Series B funding round led by Brace Pharma Capital in November 2015, raising USD 6.75 mn. CEO Aprile Pilon leads the company, guiding its strategic direction.The company specializes in developing innovative biopharmaceutical products aimed at treating severe respiratory conditions. Its core offerings focus on enhancing treatment efficacy and patient outcomes through advanced therapeutic solutions.The company's revenue model is based on multiple streams, primarily including sales from its therapeutics. Clients engage with Therabron Therapeutics through direct purchases of their biopharmaceutical products, which are structured to cater to healthcare providers and institutions.Therabron Therapeutics is planning to expand its product offerings by launching new therapeutics designed to address unmet needs in respiratory medicine. The company is focused on entering new markets across North America and Europe by the end of 2023. The recent funding from the Series B round will support these initiatives, facilitating research and development as well as market entry strategies.

## Funding rounds

- Series B, Nov 9, 2015, $6.8M — Brace Pharma Capital

## Investors

- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B